Depression treatment
Can FGF21 calm LPS-triggered despair in mice?
Open access · cc by · source: Europe PMC
rhFGF21 (0.75–3 mg/kg) improved OFT locomotion and cut FST/TST immobility after LPS 0.83 mg/kg, lowered IL-1β/TNF-α/IL-6 and NF-κB, and lost benefit with FGFR1 inhibitor PD173074.
Study at a glance
- Design
- Animal / in-vitro — Male C57BL/6N mice pretreated with rhFGF21 then LPS 0.83 mg/kg; OFT/FST/TST plus primary microglia; FGFR1 blocker PD173074
- N
- N=5 · Western blot and related assays reported n=5; three in-vivo groups with rhFGF21 0.75, 1.5, and 3 mg/kg twice daily ×3 days
- Population
- Male C57BL/6N mice (20–25 g) and primary microglia challenged with LPS
- Outcome
- Open-field, tail-suspension, and forced-swim despair tests; hippocampal cytokines, Iba1 microglia, NF-κB, and FGFR1 dependence
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
LPS cut FGF21 and caused despair-like behavior; rhFGF21 (especially 1.5–3 mg/kg) restored locomotion, reduced immobility, suppressed IL-1β/TNF-α/IL-6, and blocked microglia/NF-κB. PD173074 reversed protection, implying FGFR1.
Methodology
Pretreated male C57BL/6N mice with rhFGF21 twice daily for 3 days, injected LPS 0.83 mg/kg, then ran OFT/FST/TST and hippocampal cytokine/NF-κB/microglia assays (n=5 blots), including PD173074 co-treatment and primary microglia.
Limitations
LPS sickness is not major depressive disorder; n=5 biochemistry and male-only mice cannot establish a human antidepressant dose.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.